More young people are being diagnosed with depression than ever before. SparkRx is a treatment option with room for all of them.
Available now, at no-cost under the FDA’s Enforcement Policy during the COVID-19 public health emergency.
Limbix’s prescription digital therapeutics (PDTs) enable providers to offer evidence-based, therapeutic interventions for adolescent mental health.
PDTs require strict compliance with FDA quality management standards and are validated through rigorous clinical trials. Upon FDA clearance, PDTs can be prescribed by a doctor to treat specific medical conditions.
Our digital therapeutics are designed with valuable feedback from young people. If you’re an adolescent interested in helping Limbix design thoughtful digital experiences, email info@limbix.com!
Learn More
Limbix relies on clinical experts who provide critical product feedback to help ensure the digital therapeutics we create are evidence-based and beneficial for patients. If you are a physician looking to connect with Limbix to provide your input, please join our Physician Advisory Group.
Join Physician Advisory Group
Digital therapeutics for adolescent mental health
